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Different sources of omega-3 polyunsaturated
fatty acids affects apparent digestibility, tissue
deposition, and tissue oxidative stability in
growing female rats
Janet C Tou1,2*, Stephanie N Altman2, Joseph C Gigliotti1, Vagner A Benedito2 and Elizabeth L Cordonier3
Abstract
Background: Numerous health benefits associated with increased omega-3 polyunsaturated fatty acid (n-3 PUFA)
consumption has lead to an increasing variety of available n-3 PUFA sources. However, sources differ in the type,
amount, and structural form of the n-3 PUFAs. Therefore, the objective of this study was to determine the effect of
different sources of ω-3 PUFAs on digestibility, tissue deposition, eicosanoid metabolism, and oxidative stability.
Methods: Female Sprague-Dawley rats (age 28 d) were randomly assigned (n = 10/group) to be fed a high fat
12% (wt) diet consisting of either corn oil (CO) or n-3 PUFA rich flaxseed (FO), krill (KO), menhaden (MO), salmon
(SO) or tuna (TO) oil for 8 weeks. Rats were individually housed in metabolic cages to determine fatty acid
digestibility. Diet and tissue fatty acid composition was analyzed by gas chromatography and lipid classes using
thin layer chromatography. Eicosanoid metabolism was determined by measuring urinary metabolites of 2-series
prostaglandins (PGs) and thromoboxanes (TXBs) using enzyme immunoassays. Oxidative stability was assessed by
measuring thiobarbituric acid reactive substances (TBARS) and total antioxidant capacity (TAC) using colorimetric
assays. Gene expression of antioxidant defense enzymes was determined by real time quantitative polymerase
chain reaction (RT-qPCR).
Results: Rats fed KO had significantly lower DHA digestibility and brain DHA incorporation than SO and TO-fed
rats. Of the n-3 PUFA sources, rats fed SO and TO had the highest n-3 PUFAs digestibility and in turn, tissue
accretion. Higher tissue n-3 LC-PUFAs had no significant effect on 2-series PG and TXB metabolites. Despite higher
tissue n-3 LC-PUFA deposition, there was no increase in oxidation susceptibility indicated by no significant increase
in TBARS or decrease in TAC and gene expression of antioxidant defense enzymes, in SO or TO-fed rats.
Conclusions: On the basis that the optimal n-3 PUFA sources should provide high digestibility and efficient tissue
incorporation with the least tissue lipid peroxidation, TO and SO appeared to be the most beneficial of the n-3
PUFAs sources evaluated in this study.
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Background
The omega-6 polyunsaturated fatty acid (n-6 PUFA),
linoleic acid (LA, 18:2n-6) followed by the omega-3
polyunsaturated fatty acid (n-3 PUFA), alpha-linolenic
acid (ALA, 18:3n-3) are the primary PUFAs in the
Western diet [1]. LA and ALA are essential fatty acids
that must be obtained from the diet. Once consumed,
LA and ALA may be metabolized in the mammalian tis-
sue into long-chain PUFAs (LC-PUFAs). The major n-6
long-chain polyunsaturated fatty acid (LC-PUFA) is ara-
chidonic acid (ARA, 20:4n-6), and the bioactive n-3 LC-
PUFAs are eicosapentaenoic acid (EPA, 20:5n-3) and
docosahexaenoic acid (DHA, 20:6n-3). LA and ALA use
the same series of enzymes for biosynthesis into their
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respective LC-PUFAs and therefore, an excess of one
decreases the conversion of the other. In the Western
diet, the n-6/n-3 ratio is ~16:1; however, for optimal
health an n-6/n-3 ratio of 4:1 is recommended [2].
Increased dietary n-3 PUFAs intake promotes retina
and brain development in infants [3]. In adults, n-3
PUFA consumption has been reported to improve
health by reducing the risk of cardiovascular disease
(CVD), obesity, diabetes, inflammation, and several neu-
rological diseases [4]. Atherogenic, pro-thrombotic, and
inflammatory effects are influenced by ARA. ARA-
derived 2-series eicosanoids synthesized by the enzyme,
cyclooxygenase II (COX II), include the platelet aggre-
gating thromboxane B2 (TXB2), and the pro-inflamma-
tory prostaglandin E2 (PGE2). EPA using the same COX
II enzyme as ARA produces 3-series eicosanoids that
are less inflammatory and decrease platelet aggregation.
Therefore, increasing EPA intake may competitively
inhibit the production of ARA-derived 2-series eicosa-
noids resulting in decreased inflammation, blood-clot-
ting, and in turn, reduced CVD risk [5].
Reports of numerous health benefits have contributed
to the popularity of n-3 PUFA enriched foods and/or
supplements [6]. However, different sources of oils pro-
vide different types of n-3 PUFAs. Flaxseed oil is a rich
source of the n-3 PUFA, ALA, whereas fish oils are rich
in the n-3 LC-PUFAs, EPA and DHA. Additionally, var-
ious fish oils have different EPA:DHA ratios [7]. Similar
to fish oil, krill oil (KO) is rich in EPA and DHA. How-
ever, fatty acids from fish oils are mainly associated with
triglycerides (TGs), whereas the n-3 PUFAs in KO are
associated with phospholipids (PLs) and TGs [8]. PLs
and TGs are digested differently and in turn, this may
affect n-3 PUFA bioavailability. In human studies, feed-
ing infants DHA in PL form resulted in better absorp-
tion than feeding DHA in TG form [3]. Determining the
digestibility of n-3 PUFAs provided as PL compared to
TG is important because this influences n-3 PUFA
incorporation into tissues. Valenzuela et al. [9] reported
increased liver DHA accretion in female rats fed n-3
PUFAs in PL compared to TG form. Increasing tissue
n-3 PUFA exerts beneficial physiological effects by influ-
encing cell membrane fluidity, membrane-bound recep-
tors, signaling molecules, and gene expression [10].
However, the higher unsaturation due to increased tis-
sue n-3 PUFAs may lead to increased susceptibility to
lipid peroxidation and in turn, oxidative stress.
The effect of n-3 LC-PUFA intake on lipid peroxida-
tion has produced inconsistent results of increased oxi-
dation [11-13], no effect on oxidation [14], and even
decreased oxidation [15]. PUFAs in PL form have been
suggested to have greater stability against lipid oxidation
due to their incorporation into cell membranes [16].
However, Song et al. [11] reported that rat fed DHA in
PL form resulted in similar oxidation as feeding DHA in
TG form. Only when the accumulation of oxidants over-
whelms the body’s antioxidant enzymes does oxidative
stress and negative health effects occur. Therefore, more
studies are necessary to determine the effect of different
sources of n-3 PUFAs on tissue oxidation and tissue
antioxidant defense enzymes.
Currently, various sources of n-3 PUFAs are available
with claims that some sources are more beneficial than
others. The source of n-3 PUFAs that is most favorable
to health should provide high digestibility and efficient
tissue incorporation with the least tissue lipid peroxida-
tion. Therefore, the objective of this study was to deter-
mine the effect of different sources of n-3 PUFAs on
digestibility, tissue deposition, eicosanoid metabolism,
and oxidative stability.
Methods
Diets
Experimental diets fed to animals were formulated to
match the standard purified American Institute of
Nutrition-93G (AIN-93 G) diet which meets the nutri-
tional requirements for growing rats as defined by the
National Research Council [17]. Modifications of the
AIN-93G diet consisted of replacing 7% lipids with 12%
lipid by weight. The high fat diet (~27% by kcals) was
used to reflect the higher total fat intake typical of the
Western diet (~33% by kcals). The dietary oils consisted
of either: 1) corn oil (CO), 2) flaxseed oil (FO), 3) krill
oil (KO), 4) menhaden oil (MO), 5) salmon oil (SO) or
6) tuna oil (TO). CO, FO, MO, SO, and TO sources
were provided by J. Edwards International Inc. (Quincy,
MA). KO was purchased from Enzymotec Ltd. (Morris-
town, NJ). It was necessary to add CO (2 g/kg diet) to
the MO and KO (10 g/kg diet) diets to meet the
National Research Council [17] nutrient recommenda-
tion in rats for the essential n-6 PUFA, linoleic acid
(LA, 18:2n-6) (Table 1).
Table 2 shows the fatty acid composition and lipid
classes of the experimental oil. The lipid sources were
selected on the basis that CO is prevalent in the Wes-
tern diet and provides a high n-6:n-3 ratio of 73:1. FO is
the richest source of the essential n-3 PUFA, ALA [18].
The EPA:DHA ratio of 5:1 in SO was higher than 1:2 in
TO. KO and MO have a similar EPA:DHA ratio of 3:1;
however, fatty acids in MO are in TG form and fatty
acids in KO are in PL as well as TG form (Table 2).
Animal Feeding Study
All animal procedures were approved by the Animal
Care and Use Committee at West Virginia University
and were conducted in accordance with the guidelines
set forth by the National Research Council Guide for
the Care and Use of Laboratory Animals [19]. Growing
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(28 d) female Sprague-Dawley rats (n = 60) were pur-
chased from Taconic Farms (Rockville, MD). Upon arri-
val at the West Virginia University animal care facility,
rats were individually caged in metabolic cages to deter-
mine food intake and to collect urine and fecal samples.
Rats were kept housed in rooms maintained at 21°C
with a 12 h light/dark cycle throughout the 8 weeks
feeding study. Following 7 d acclimation, rats (n = 10/
group) were randomly assigned to the experimental
diets of CO, FO, KO, MO, SO or TO. Rats were pro-
vided 15 ± 0.75 g diet/d of their assigned diet to prevent
variability in food intake. This amount was based on the
daily average food consumed by growing female Spra-
gue-Dawley rats fed diets containing different sources of
n-3 PUFAs [20]. Food intake was measured and fresh
diet was provided daily. Water consumption and body
weights were measured weekly throughout the 8 week
feeding study.
Determination of Lipid and Fatty Acid Apparent
Digestibility
Lipid intake was determined as diet consumed per week
× 12% lipid in the diet. Fatty acid intake was determined
as diet consumed per week ×% fatty acid in the diet.
Lipid apparent digestibility was determined by collecting
fecal samples during the final week of the 8 feeding
week study. Rats were individually housed in metabolic
cages to collect feces. Pooled 7 d fecal samples were
freeze-dried (VirTis, Warminster, PA), weighed, and
total fecal lipid content determined by Soxhlet extrac-
tion [21]. Apparent digestibility of total lipid was mea-
sured according to Deuchi et al [22] as [(lipid intake -
fecal lipid)/(lipid intake)] × 100. Similarly, apparent
digestibility of individual fatty acids was measured using
the formula [(fatty acid intake - fecal fatty acids)/(fatty
acid intake)] × 100.
Table 1 Whole Diet Composition
Treatments
Ingredients (g/kg diet) CO FO KO MO SO TO
ω-3 PUFA Oil Source 0 120 118 118 120 120
Corn Oil 120 0 2 2 0 0
Casein 200 200 200 200 200 200
L-Cystine 3 3 3 3 3 3
Corn Starch 347.5 347.5 347.5 347.5 347.5 347.5
Maltodextrin 132 132 132 132 132 132
Sucrose 100 100 100 100 100 100
Cellulose 50 50 50 50 50 50
Mineral Mix, AIN-93G-MX1 35 35 35 35 35 35
Vitamin Mix, AIN-93-VX1 10 10 10 10 10 10
Choline Bitartrate 2.5 2.5 2.5 2.5 2.5 2.5
1 Based on the AIN-93G vitamin and mineral mixes [63].
Abbreviations are CO, corn oil; FO, flaxseed oil; KO, krill oil; MO, menhaden oil;
SO, salmon oil; TO, tuna oil
Table 2 Dietary fatty acids and lipid classes
Treatments
Fatty Acids (mg FA/g Diet)1 CO FO KO MO SO TO
n-3 PUFA 0.1 ± 0.01 14.6 ± 2.1 18.0 ± 4.6 7.7 ± 0.5 12.0 ± 0.8 5.6 ± 0.5
ALA (18:3n-3) 0.1 ± 0.01 14.6 ± 2.1 0.2 ± 0.04 0.2 ± 0.01 0.1 ± 0.01 0.1 ± 0.01
TG2 100 100 2.4 ± 0.1 100 100 100
PL2 ND ND 1.8 ± 0.1 ND ND ND
EPA (20:5n-3) ND ND 13.2 ± 2.8 5.5 ± 0.4 10.0 ± 0.7 2.6 ± 0.3
TG2 ND ND 20.9 ± 0.9 100 100 100
PL2 ND ND 27.2 ± 0.7 ND ND ND
DHA (22:6n-3) ND ND 4.6 ± 1.9 2.0 ± 0.2 1.9 ± 0.1 2.9 ± 0.2
TG2 ND ND 11.1 ± 0.3 100 100 100
PL2 ND ND 12.8 ± 0.5 ND ND ND
EPA/DHA ND ND 3:1 3:1 5:1 1:2
n-6 PUFA 6.4 ± 0.9 5.4 ± 0.80 0.5 ± 0.1 0.2 ± 0.1 0.5 ± 0.1 0.5 ± 0.1
LA (18:2n-6) 6.4 ± 0.9 5.4 ± 0.8 0.5 ± 0.1 0.2 ± 0.1 0.5 ± 0.1 0.2 ± 0.03
TG2 100 100 6.9 ± 0.5 100 100 100
PL2 ND ND 2.8 ± 0.03 ND ND ND
ARA (20:4n-6) ND ND 0.23 ± 0.04 0.16 ± 0.01 0.22 ± 0.01 0.30 ± 0.1
TG2 ND ND ND 100 100 100
PL2 ND ND 1.4 ± 0.2 ND ND ND
n-6/n-3 73:1 1:3 1:33 1:48 1:23 1:12
1Values are expressed as mean (mg FA/g diet) ± SEM
2Values are expressed as mean (%) ± SEM
Abbreviations are CO, corn oil; FO, flaxseed oil; KO, krill oil; MO, menhaden oil; SO, salmon oil; TO, tuna oil; TG, triglyceride; PL, phospholipid; ALA, a-linolenic
acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; LA, linoleic acid; ARA, arachidonic acid; ND, not detectable.
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Determination of Fatty Acid Composition
At the end of the 8 weeks, rats were euthanized by CO2
inhalation. Brain, liver, retroperitoneal and gonadal adi-
pose tissue was dissected and then weighed. Tissues
were immediately frozen in liquid nitrogen and stored at
-80°C until analyzed. Lipids were extracted according to
Bligh and Dyer [23]. Briefly, aliquots of brain (0.5 g),
liver (0.5 g) or adipose tissue (0.025 g) samples were
added to Tris/EDTA buffer (pH 7.4) and 48 μl nonade-
cenoic (19:1) added as an internal standard. Chloroform:
methanol:acetic acid (2:1:0.15 v/v/v) solution was added
and samples were centrifuged at 900 g for 10 min at 10°
C. The collected chloroform layer was filtered through
1-phase separation filters. The centrifugation and filtra-
tion steps were repeated and the extracted lipid was
dried under nitrogen gas. All samples were conducted in
duplicate.
The extracted lipid samples were transmethylated
according to Fritsche and Johnston [24]. Briefly, fatty
acids were methylated by adding 4% sulfuric acid in
anhydrous methanol to the extracted lipid samples fol-
lowed by incubation in a 90°C water bath for 60 min.
Samples were cooled to room temperature and 3 mL of
deionized distilled water added. Chloroform was added
to the methylated samples and centrifuged at 900 g for
10 min at 10°C. The collected chloroform layer was fil-
tered through anhydrous sodium sulfate to remove
remaining water. Samples were dried under nitrogen
gas. Dried samples were diluted in iso-octane to a con-
centration of 5 mg FAME (fatty acid methyl esters)/mL
iso-octane. All samples were conducted in duplicate.
FAME samples were analyzed by gas chromatography
(CP-3800, Varian, Walnut Creek, CA) using an initial
temperature of 140°C held for 5 min and then increased
1°C per min to a final temperature of 220°C. Total
separation time was 60 min. A wall-coated open tubular
fused silica capillary column (Varian Inc., Walnut Creek,
CA) was used to separate FAMEs with CP-Sil 88 as the
stationary phase. Nitrogen was used as the carrier gas.
Quantitative 37 Component FAME Sigma Mix (Supelco,
Bellefonte, PA) was used as a standard to identify fatty
acids. Fatty acids were quantified using peak area counts
and retention time.
Analysis of Lipid Classes
Lipid classes were separated using thin-layer chromato-
graphy (TLC) as described in Gigliotti et al. [8]. Briefly,
tissue lipid samples were spotted (40 μl) onto Whatman
K6F 60Å pore size silica plates containing fluorocein (PJ
Cobert Associates, St. Louis, MO). TLC plates were
developed using a hexane:ether:acetic acid solution
(80:20:1.5 v:v:v) as the mobile phase. The separated lipid
classes were visualized using a Fluorochem 8000 densit-
ometer (Alpha Innotech Corp, San Leandro, CA). TLC
plate images were photographed using a camera inter-
faced to the PC and images were analyzed using the
spot densitometer Fluorochem program (version 1.0).
TGs were identified using the retention factor (Rf)
values obtained from a triolein standard (Sigma-Aldrich,
St. Louis, MO). PLs were identified using the Rf value of
soybean lecithin standard (Fisher Scientific, Pittsburgh,
PA). Identified lipid classes were scraped from the plates
then lipids extracted, methylated, and fatty acid compo-
sition determined by gas chromatography according to
the methods described above.
Eicosanoid Measurements
TXB2 and PGE2 derived from ARA are short-lived mole-
cules. Therefore, the stable metabolites 11-dehydro
TXB2 and 13, 14-dihydro-15-keto PGE2 were measured.
Pooled 7 d urine samples were collected during the final
week of the 8 wk feeding study. Rats were individually
housed in metabolic cages to collect urine. Ascorbic
acid (0.1%) was added to the urine collection tubes as a
preservative, and mineral oil (1 mL) was added to pre-
vent evaporation. Pooled 7 d urine samples were centri-
fuged at 1, 500 g for 10 min at 4°C. Following
centrifugation, urine samples were aliquoted into clean
tubes. Urinary 11-dehydro TXB2 and 13, 14-dihydro-15-
keto PGE2 were determined using a commercially avail-
able enzyme immunoassay kit according to the manu-
facturer’s instructions (Cayman Chemical, Ann Arbor,
MI). Absorbance was determined at wavelength 405 nm
using a Spectramax Plus microplate reader (Molecular
Devices, Sunnyvale, CA).
Measurement of Oxidative Stability
The rats were euthanized by CO2 inhalation. The chest
cavity was opened and the aorta punctured to collect
blood. Blood was centrifuged at 1, 500 g for 10 min at
4°C to obtain serum. Samples were stored at -80°C until
assayed. Serum and liver thiobarbituric acid reactive
substances (TBARS) were determined. Liver homogenate
was prepared by homogenizing tissue (~0.025 g) in 250
μl of Tris/EDTA buffer (pH 7.4) using a polytron homo-
genizer. Samples were centrifuged at 1, 500 g for 15 min
and the supernatant collected. TBARS were measured
using a commercially available colorimetric kit (Cayman
Chemical, Ann Arbor, MI). Absorbance was determined
at 540 nm using a Spectramax Plus microplate reader.
All samples were determined in duplicate and TBARS
values were expressed as μM/malondialdehyde (MDA).
Total antioxidant capacity (TAC) was measured using
a commercially available total antioxidant assay colori-
metric assay kit (Cayman Chemical, Ann Arbor, MI).
Briefly, serum TAC was determined by diluting serum
samples 1:20 v/v with 5 mM potassium phosphate buffer
(pH 7.4) containing 0.9% sodium chloride and 0.1%
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glucose. Liver homogenates were prepared in 1 mL of 5
mM potassium phosphate buffer (pH 7.4). Absorbance
was determined at 750 nm using a Spectramax Plus
microplate reader. All samples were determined in
duplicate and values were expressed as Trolox
equivalents.
RNA Isolation and Gene Expression
Gene expression of antioxidant enzymes was measured
by isolating total RNA from liver tissue using the mir-
Vana™ miRNA Isolation Kit (Ambion Inc, Foster City,
CA) according to the manufacturer’s instructions for
total RNA isolation. The concentration of total RNA
was quantified using a NanoDrop 1000 spectrophot-
ometer (Thermo Scientific, Waltham, MA). RNA integ-
rity was assessed by agarose gel electrophoresis. First-
strand complementary DNA (cDNA) was synthesized
using the SuperScript III First-Strand Synthesis System
(Invitrogen, Carlsbad, CA), according to the manufac-
turer’s instructions with oligo(dT)20 and 600 ng of RNA.
To determine superoxide dismutase (SOD), catalase
(CAT), and glutathione-peroxidase (GSH-Px) gene
expression, cDNA were amplified in triplicate by RT-
qPCR using an iCycler iQ Real-Time PCR Detection
System (BioRad, Hercules, CA) in a 5 μl reaction
volume using 2.5 μl 2X SYBR Green PCR Master Mix
(Applied Biosystems, Carlsbad, CA) with 100 nM of
each primer and 1 μL of diluted 1:10 cDNA sample.
The primer sequence for Zinc/Copper (Zn/Cu SOD)
SOD 1 was (forward 5’ - GGT CCA CGA GAA ACA
AGA TGA - 3’, reverse 5’ - CAA TCA CAC CAC AAG
CCA AG - 3’), manganese (Mn SOD) SOD 2 was (for-
ward 5’ - GAA AGT GCT CAA GAT GGA CAA AG -
3’, reverse 5’ - CTG AAT GGC TTC CCT GAA TG -
3’), CAT was (forward 5’ - TGT TGA ATG AGG AGG
AGA GGA - 3’, reverse 5’ - TTC TTA GGC TTC TGG
GAG TTG - 3’), and GSH-Px was (forward 5’ - GAT
ACG CCG AGT GTG GTT T - 3’, reverse 5’ - TCT
TGA TTA CTT CCT GGC TCC T - 3’). The house-
keeping gene GAPDH was used as an internal reference
(forward 5’ - TCA AGA AGG TGG TGA AGC AG - 3’,
reverse 5’ - CCT CAG TGT AGC CCA GGA TG - 3’).
The program used for qRT-PCR amplification consisted
of an initial temperature at 50°C for 2 min followed by
an initial denaturation for 10 min at 95°C and 40 PCR
cycles. Each cycle comprised a melting step at 95°C for
15 sec followed by a joint annealing/extension step at
60°C for 1 min. Specificity of amplification was assessed
by a melting curve of each amplicon, and visualization
of the expected fragment size on 3% agarose gel. Data
were expressed as relative gene expression after normali-
zation to the GAPDH housekeeping gene. The Pfaffl
relative quantification model was used for gene expres-
sion calculation [25].
Statistical Analysis
Values were expressed as mean ± standard error of the
mean (SEM). One-way analysis of variance (ANOVA)
was used to determine differences among treatment
groups. Post-hoc multiple comparisons were performed
using Tukey’s test. Differences were considered signifi-
cant at P < 0.05. Results were analyzed using SigmaStat
3.1 statistical software (Systat Software Inc., San Jose,
CA).
Results
Food Intake, Body and Tissue Weight
No significant differences were observed for food intake,
body weight gain or final body weight among the diet
groups (Table 3). Rats fed SO or TO had heavier liver
weight (P < 0.001) compared to MO, FO or CO-fed
rats. KO-fed rats had heavier (P < 0.001) liver weights
than FO or CO-fed rats. There were no significant dif-
ferences in brain, gonadal or retroperitoneal adipose tis-
sue weights among the diet groups (Table 3).
Diet Fatty Acid Content and Apparent Digestibility
Shown in Table 2, KO had the highest total n-3 PUFA
content followed by FO. Of the oil sources, FO had the
highest ALA content and KO had the highest EPA and
DHA content. Of the fish oils, SO had the highest EPA
content and TO had the highest DHA content. Dietary
n-3 PUFAs were in TG form in FO and fish oil sources.
In KO, n-3 PUFAs were approximately equally distribu-
ted in TGs and PLs.
Shown in Table 4, apparent ALA digestibility was
greater (P = 0.005) in rats fed FO compared to TO or
CO-fed rats. Apparent ALA digestibility was greater (P
< 0.001) in KO, MO, and SO than CO-fed rats. No sig-
nificant differences were observed in the apparent EPA
digestibility among rats fed the different marine oils.
However, apparent DHA digestibility was higher (P =
0.009) in SO than KO-fed rats. There were no signifi-
cant differences in apparent DHA digestibility in rats
fed MO or TO compared to SO or KO-fed rats.
Shown in Table 2, dietary n-6 PUFAs were in TG
form in FO and fish oil sources. In KO, the n-6 PUFA,
LA was predominantly in the TG form, whereas ARA
was in PL form. Shown in Table 4, apparent LA digest-
ibility was lower (P < 0.001) in TO-fed rats than all
groups, except MO. Apparent LA digestibility was sig-
nificantly lower in MO than SO, FO or CO-fed rats. No
significant differences were observed in apparent ARA
digestibility among the diet groups. Apparent digestibil-
ity of total lipids was lowest (P < 0.02) in rats fed KO.
Apparent digestibility of total lipids was greater (P =
0.008) in SO and TO than CO-fed rats. SO fed rats also
had greater (P = 0.02) apparent total lipid digestibility
than FO-fed rats
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Tissue Deposition
Brain Fatty Acid Profile
The major lipid class in the brain was PL (54.2-63.1%)
with the remaining portion consisting of polar non-PLs
(36.9-45.8%). SO and TO-fed rats had the highest (P <
0.001) brain DHA deposition. Rats fed KO had signifi-
cantly higher brain DHA than FO-fed rats. There were
no significant differences in brain DHA deposition in
rats fed MO compared to KO, FO or CO-fed rats. Brain
EPA deposition was lower (P = 0.01) in rats fed TO
compared to MO and FO-fed rats. Brain EPA was not
detectable in CO-fed rats. Brain ALA deposition was
not significantly different among the diet groups. Over-
all, rats fed SO and TO had the highest (P < 0.007)
brain n-3 PUFA deposition (Table 5).
Regarding n-6 PUFAs, brain LA deposition was high-
est (P < 0.001) in CO and FO-fed rats. Brain LA deposi-
tion was also higher (P = 0.007) in KO and MO than
SO or TO-fed rats. Brain ARA deposition was signifi-
cantly higher (P < 0.03) in SO, TO or CO compared to
FO, MO and KO-fed rats. Overall, total n-6 PUFA con-
tent in the brain was significantly lower in MO, FO,
TO, and KO than SO or CO-fed rats (Table 5).
Liver Fatty Acid Profile
Shown in Table 6, total n-3 PUFA deposition in the liver
was highest (P < 0.001) in SO and TO-fed rats. Liver con-
tent of specific n-3 PUFAs was also evaluated. Liver ALA
deposition was highest (P < 0.001) in FO-fed rats with
ALA stored mainly as TGs. Of the n-3 LC-PUFAs, liver
EPA deposition was highest (P < 0.001) in SO-fed rats.
EPA was not detectable in the liver of CO-fed rats. FO
had lower (P = 0.02) liver EPA-TG compared to KO, MO
or SO-fed rats. FO and KO-fed rats had highest (P =
0.002) liver EPA-PL. Rats fed SO and TO had the highest
(P < 0.001) liver DHA deposition. In rats fed fish oil,
DHA was mainly stored in TG (18-23%) compared to PL
(13-16%). In KO-fed rat, liver DHA was almost equally
stored in TGs (14.9 ± 0.6%) and PLs (15.5 ± 0.5%).
Evaluation of specific n-6 PUFAs showed rats fed FO
or marine oils had lower (P < 0.001) liver LA deposition
Table 3 The effect of feeding growing female rats different sources of omega-3 polyunsaturated fatty acids on food
intake, body weight, and tissue weights
Treatments
Measurement1 CO FO KO MO SO TO
Food intake (g) 750.1 ± 12.5 762.9 ± 14.3 767.4 ± 10.9 761.2 ± 17.6 706.8 ± 17.4 738.3 ± 16.4
Body weight gain (g) 76.0 ± 7.4 103.8 ± 8.1 98.4 ± 6.1 107.6 ± 12.5 86.0 ± 8.4 106.0 ± 6.7
Final body weight (g) 214.9 ± 6.4 239.6 ± 8.2 231.7 ± 6.6 241.5 ± 14.4 215.5 ± 10.3 235.0 ± 8.2
Liver weight (g/100 g bwt) 2.9 ± 0.1c 2.8 ± 0.1c 3.6 ± 0.1ab 3.2 ± 0.2bc 3.7 ± 0.1a 3.8 ± 0.1a
Brain weight (g/100 g bwt) 0.8 ± 0.03 0.8 ± 0.03 0.8 ± 0.02 0.8 ± 0.04 0.8 ± 0.04 0.8 ± 0.03
Gonadal adipose weight (g/100 g bwt) 1.1 ± 0.2 1.7 ± 0.2 1.6 ± 0.1 1.8 ± 0.4 1.3 ± 0.2 1.3 ± 0.2
Retroperitoneal adipose weight (g/100 bwt) 0.3 ± 0.04 0.5 ± 0.06 0.4 ± 0.04 0.5 ± 0.07 0.4 ± 0.07 0.3 ± 0.06
1Values are expressed as the mean ± SEM of n = 10 rats/group. Different superscript letters a, b, c within the same rows indicate significant differences at P <
0.05 by one-way ANOVA followed by Tukey’s test. Abbreviations are CO, corn oil; FO, flaxseed oil; KO, krill oil; MO, menhaden oil; SO, salmon oil; TO, tuna oil;
bwt, body weight.
Table 4 The effect of feeding growing female rats different sources of omega-3 polyunsaturated fatty acids on
apparent digestibility
Treatments
Measurements (%)1 CO FO KO MO SO TO
Total Lipid 95.9 ± 0.4c 96.8 ± 0.3bc 93.1 ± 0.7d 97.2 ± 0.4abc 98.8 ± 0.2a 98.0 ± 0.2ab
n-3 PUFAs
ALA (18:3n-3) 90.2 ± 2.4c 99.8 ± 0.02a 97.2 ± 0.2ab 96.4 ± 0.8ab 97.7 ± 0.4ab 94.1 ± 0.7bc
EPA (20:5n-3) ND ND 98.7 ± 0.6 98.8 ± 0.7 98.9 ± 0.6 98.9 ± 0.5
DHA (22:6n-3) ND ND 99.4 ± 0.1b 99.7 ± 0.1ab 99.8 ± 0.04a 99.6 ± 0.1ab
n-6 PUFAs
LA (18:2n-6) 99.4 ± 0.2a 99.7 ± 0.03a 98.9 ± 0.1ab 97.8 ± 0.3bc 99.6 ± 0.1a 97.5 ± 0.6c
ARA (20:4n-6) ND ND 97.7 ± 0.3 97.8 ± 0.2 96.8 ± 0.7 96.8 ± 0.6
1 Values are expressed as the mean ± SEM of n = 10 rats/group. Different superscript letters a, b, c, d within the same rows indicate significant differences at P <
0.05 by one-way ANOVA followed by Tukey’s test. Abbreviations are CO, corn oil; FO, flaxseed oil; KO, krill oil; MO, menhaden oil; SO, salmon oil; TO, tuna oil;
PUFA, polyunsaturated fatty acids; ALA, a-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; LA, linoleic acid; ARA, arachidonic acid; ND, not
detectable.
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than CO-fed rats. Rats fed marine oils had lower (P =
0.01) liver LA deposition than FO-fed rats. Similarly,
liver LA-TG and PL was significantly decreased in rats
fed marine oils compared to FO or CO-fed rats. The n-
6 LC-PUFA, liver ARA was mainly stored in PL form
(9.4-26%) rather than TG form (0.6-4.3%) in all diet
groups. Rats fed TO (P < 0.001) had the highest liver
ARA deposition. Rats fed FO, MO and KO had lower (P
< 0.001) liver ARA than TO, SO or CO-fed rats. Liver
total n-6 PUFA deposition in the liver was lower (P <
0.001) in rats fed FO or marine oils compared to CO-
fed rats. Additionally, MO and KO-fed rats had lower (P
= 0.01) total n-6 PUFA deposition than FO, SO or TO-
fed rats (Table 6).
Adipose Fatty Acid Profile
Fatty acids were predominantly in TG form in adipose
tissues (data not shown). In gonadal adipose tissue, ALA
deposition was highest (P < 0.001) in FO-fed rats. EPA
deposition was highest (P = 0.04) in KO-fed rats.
Neither EPA nor DHA were detectable in CO-fed rats.
EPA and DHA were detectable in the gonadal adipose
tissue of rats fed FO. DHA deposition was higher (P <
Table 5 The effect of feeding growing female rats different sources of omega-3 polyunsaturated fatty acids on brain
fatty acid profile
Treatments
Fatty Acid Measurement1 CO FO KO MO SO TO
n-3 PUFA 4.7 ± 0.5b 4.1 ± 0.3b 5.6 ± 0.5b 5.3 ± 0.3b 9.2 ± 0.5a 7.7 ± 0.4a
ALA (18:3n-3) 0.4 ± 0.05 0.3 ± 0.07 0.4 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.5 ± 0.1
EPA (20:5n-3) ND 0.4 ± 0.1a 0.2 ± 0.03ab 0.4 ± 0.1a 0.2 ± 0.02ab 0.1 ± 0.003b
DHA (22:6n-3) 4.3 ± 0.5bc 3.4 ± 0.2c 5.0 ± 0.5b 4.5 ± 0.1bc 8.5 ± 0.5a 7.2 ± 0.3a
n-6 PUFA 3.7 ± 0.4a 2.2 ± 0.1bc 2.3 ± 0.1bc 2.1 ± 0.1c 3.4 ± 0.1a 3.0 ± 0.1b
LA (18:2n-6) 0.4 ± 0.03a 0.3 ± 0.02a 0.2 ± 0.02b 0.2 ± 0.01b 0.1 ± 0.005c 0.05 ± 0.004c
ARA (20:4n-6) 3.3 ± 0.4a 1.9 ± 0.1b 2.1 ± 0.1b 2.0 ± 0.1b 3.4 ± 0.1a 2.9 ± 0.1a
1Values are expressed as mean (mg FA/g tissue) ± SEM of n = 10 rats/group. Different superscript letters a, b, c within the same rows indicate significant
differences at P < 0.05 by one-way ANOVA followed by Tukey’s test. Abbreviations are CO, corn oil; FO, flaxseed oil; KO, krill oil; MO, menhaden oil; SO, salmon
oil; TO, tuna oil; PUFA, polyunsaturated fatty acids; ALA, a-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; LA, linoleic acid; ARA,
arachidonic acid; ND, not detectable.
Table 6 The effect of feeding growing female rats different sources of omega-3 polyunsaturated fatty acids on liver
fatty acid profile
Treatments
Fatty Acid Measurement1 CO FO KO MO SO TO
n-3 PUFA 0.9 ± 0.1b 7.8 ± 1.0b 9.6 ± 1.3b 9.5 ± 1.1b 43.6 ± 5.8a 35.9 ± 2.5a
ALA (18:3n-3) 0.1 ± 0.01b 4.4 ± 0.7a 0.1 ± 0.01b 0.3 ± 0.1b 0.3 ± 0.1b 0.2 ± 0.04b
TG2 0.4 ± 0.03b 21.0 ± 1.6a 0.8 ± 0.1b 1.7 ± 0.2b 1.0 ± 0.1b 0.7 ± 0.1b
PL2 0.1 ± 0.03b 0.9 ± 0.1a 0.3 ± 0.03b 0.3 ± 0.2b 0.1 ± 0.05b 0.1 ± 0.05b
EPA (20:5n-3) ND 1.7 ± 0.2b 3.7 ± 0.5b 3.0 ± 0.6b 19.4 ± 3.1a 6.3 ± 0.6b
TG2 ND 2.9 ± 0.1c 7.5 ± 0.8a 6.8 ± 0.6ab 7.3 ± 0.8a 4.0 ± 0.5bc
PL2 ND 8.9 ± 1.0a 7.2 ± 0.7a 3.7 ± 0.6bc 4.3 ± 0.3b 2.0 ± 0.1c
DHA (22:6n-3) 0.9 ± 0.1b 1.7 ± 0.2b 5.7 ± 0.8b 6.2 ± 0.7b 23.8 ± 2.9a 29.4 ± 2.0a
TG2 1.0 ± 0.1c 1.0 ± 0.1c 14.9 ± 0.6b 18.2 ± 1.1ab 20.2 ± 1.1ab 23.5 ± 1.6a
PL2 5.2 ± 0.7c 9.5 ± 0.6bc 15.5 ± 0.5ab 13.7 ± 2.9ab 13.7 ± 0.9ab 16.1 ± 0.9a
n-6 PUFA 11.9 ± 0.9a 5.9 ± 0.9b 3.0 ± 0.1c 2.7 ± 0.3c 6.7 ± 0.6b 7.6 ± 0.5b
LA (18:2n-6) 7.1 ± 0.7a 4.1 ± 0.7b 1.4 ± 0.1c 1.3 ± 0.2c 2.0 ± 0.4c 1.6 ± 0.2c
TG2 35.8 ± 1.6a 15.6 ± 0.5b 5.9 ± 0.4c 5.7 ± 0.5c 5.0 ± 0.4c 4.2 ± 0.2c
PL2 9.9 ± 0.8a 11.7 ± 0.6a 3.4 ± 0.b 3.2 ± 0.4b 2.7 ± 0.3b 2.3 ± 0.3b
ARA (20:4n-6) 4.8 ± 0.3b 1.9 ± 0.3c 1.6 ± 0.1c 1.4 ± 0.1c 4.7 ± 0.3b 6.0 ± 0.4a
TG2 4.3 ± 0.5a 0.6 ± 0.1c 0.8 ± 0.1c 1.2 ± 0.2bc 1.4 ± 0.1bc 2.1 ± 0.2b
PL2 26.0 ± 0.9a 12.4 ± 0.7bc 9.4 ± 0.5c 10.0 ± 1.9c 11.7 ± 0.7c 15.3 ± 0.7b
1Values are expressed as mean (mg FA/g tissue) ± SEM of n = 10 rats/group.
2Values are expressed as mean (%) ± SEM of n = 10 rats/group.
Different superscript letters a, b, c within the same rows indicate significant differences at P < 0.05 by one-way ANOVA followed by Tukey’s test. Abbreviations
are CO, corn oil; FO, flaxseed oil; KO, krill oil; MO, menhaden oil; SO, salmon oil; TO, tuna oil; PUFA, polyunsaturated fatty acids; ALA, a-linolenic acid; EPA,
eicosapentaenoic acid; DHA, docosahexaenoic acid; LA, linoleic acid; ARA, arachidonic acid; TG, triglyceride; PL, phospholipid; ND, not detectable.
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0.001) in KO, MO, and TO than FO-fed rats. Rats fed
MO and TO also had higher (P = 0.03) DHA deposition
than SO-fed rats. Total n-3 PUFA deposition was high-
est (P < 0.001) in FO-fed rats. KO and MO-fed rats had
higher (P = 0.002) total n-3 PUFA deposition than CO-
fed rats.
TO-fed rats had the highest (P = 0.03) ARA deposition.
LA and total n-6 PUFA deposition was lower (P < 0.001)
in rats fed FO and marine oils compared to CO-fed rats.
Rats fed marine oils also had lower (P < 0.001) LA and
total n-6 PUFA deposition than FO-fed rats (Table 7).
In retroperitoneal adipose tissue, ALA deposition was
highest (P < 0.001) in FO-fed rats. EPA deposition was
highest (P < 0.001) in KO-fed rats. EPA was not detect-
able in CO-fed rats. Rats fed FO had lower (P = 0.006)
EPA deposition than KO, MO or SO-fed rats. DHA was
not detectable in the retroperitoneal adipose of CO or
FO-fed rats. DHA deposition was higher (P < 0.04) in
KO and MO than SO-fed rats. Overall, total n-3 PUFA
deposition was highest (P < 0.001) in FO-fed rats. Rats
fed KO or MO had greater (P = 0.001) total n-3 PUFA
deposition than CO-fed rats.
Regarding n-6 PUFA deposition, retroperitoneal adi-
pose tissue LA deposition was lower (P < 0.001) in rats
fed FO and marine oils compared to CO-fed rats. Rats
fed marine oils had lower (P = 0.006) LA deposition
compared to FO-fed rats. Retroperitoneal adipose tissue
ARA was lowest (P < 0.001) in FO-fed rats. Total n-6
PUFA deposition was lower (P < 0.001) in rats fed FO
and marine oils compared to CO-fed rats. Rats fed mar-
ine oils also had lower (P = 0.01) total n-6 PUFA
deposition than FO-fed rats (Table 7).
Eicosanoids Production and Oxidative Stability
There were no significant differences in urinary 13, 14-
dihydro-15-keto PGE2 or 11-dehydro-TXB2 among the
diet groups (Table 8). There were no differences in RBC
TBARS among the diet groups. Serum TBARS were
lower (P = 0.005) in SO and TO than CO, KO or MO-
fed rats. However, there were no differences in serum
TAC among the treatment groups. Liver TBARS were
highest (P = 0.03) in MO-fed rats. Rats fed MO also had
greater (P = 0.03) liver TAC than KO, SO or TO-fed
rats (Table 8). There were no significant differences in
relative gene expression of Zn/Cu SOD (Figure 1A), Mn
SOD (Figure 1B), CAT (Figure 1C) or GSH-Px (Figure
1D) among the dietary treatment groups.
Discussion
The variety of commercially available n-3 PUFA sources
raises the question of which is the most beneficial. In
KO, PUFAs are mainly in PL form whereas in fish oils,
PUFAs are mainly in TG form, leading to claims that n-
3 LC-PUFAs are better absorbed as KO than fish oils
[26]. This study compared sources of n-3 PUFAs that
differed in the amount, type, and/or structural form of
n-3 PUFAs.
Table 7 The effect of feeding growing female rats different sources of omega-3 polyunsaturated fatty acids on
gonadal and retroperitoneal adipose tissue fatty acid profile
Treatments
Fatty Acid Measurement1 CO FO KO MO SO TO
Gonadal Fat Pad
n-3 PUFA 1.3 ± 0.2c 81.7 ± 6.8a 21.5 ± 2.6b 21.6 ± 2.0b 9.5 ± 2.8bc 13.5 ± 2.4bc
ALA (18:3n-3) 1.3 ± 0.2b 80.9 ± 6.6a 3.1 ± 0.4b 5.0 ± 0.4b 1.1 ± 0.2b 2.0 ± 0.4b
EPA (20:5n-3) ND 0.7 ± 0.2c 9.7 ± 1.3a 5.6 ± 0.9b 4.2 ± 1.4bc 1.9 ± 0.4bc
DHA (22:6n-3) ND 0.07 ± 0.02c 8.7 ± 1.2ab 10.9 ± 1.0a 4.2 ± 1.2bc 9.7 ± 2.0a
n-6 PUFA 107.9 ± 14.1a 59.8 ± 5.8b 17.0 ± 2.0c 21.0 ± 1.8c 8.0 ± 1.4c 11.6 ± 2.2c
LA (18:2n-6) 106.5 ± 13.9a 59.4 ± 5.6b 15.5 ± 1.9c 19.5 ± 1.7c 6.5 ± 1.3c 8.5 ± 1.6c
ARA (20:4n-6) 1.4 ± 0.2b 0.5 ± 0.1b 1.6 ± 0.2b 1.5 ± 0.1b 1.4 ± 0.3b 3.1 ± 0.7a
Retroperitoneal Fat Pad
n-3 PUFA 2.9 ± 0.2c 149.4 ± 15.1a 45.7 ± 6.9b 37.9 ± 5.1b 20.4 ± 4.3bc 23.1 ± 3.6bc
ALA (18:3n-3) 2.9 ± 0.2b 148.4 ± 15.1a 5.0 ± 0.6b 8.0 ± 0.7b 2.7 ± 0.3b 2.8 ± 0.6b
EPA (20:5n-3) ND 1.0 ± 0.2c 19.9 ± 3.1a 10.8 ± 1.6b 10.5 ± 2.3b 3.2 ± 0.7bc
DHA (22:6n-3) ND ND 20.7 ± 3.9a 23.3 ± 2.1a 9.4 ± 1.9b 17.0 ± 2.8ab
n-6 PUFA 211.3 ± 25.4a 97.7 ± 10.3b 34.4 ± 4.9c 33.6 ± 5.0c 14.8 ± 2.8c 13.9 ± 1.8c
LA (18:2n-6) 208.9 ± 25.2a 97.2 ± 10.3b 32.1 ± 4.9c 34.4 ± 3.4c 14.6 ± 2.5c 11.4 ± 1.7c
ARA (20:4n-6) 2.4 ± 0.3ab 0.5 ± 0.1c 2.3 ± 0.3ab 2.9 ± 0.2a 1.8 ± 0.2b 2.5 ± 0.2ab
1Values are expressed as mean (mg FA/g tissue) ± SEM of n = 10 rats/group. Different superscript letters a, b, c within the same rows indicate significant
differences at P < 0.05 by one-way ANOVA followed by Tukey’s test. Abbreviations are CO, corn oil; FO, flaxseed oil; KO, krill oil; MO, menhaden oil; SO, salmon
oil; TO, tuna oil; PUFA, polyunsaturated fatty acids; ALA, a-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; LA, linoleic acid; ARA,
arachidonic acid; ND, not detectable.
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Apparent Digestibility
PUFA digestibility was influenced by the structural form.
In our study, DHA content was ~2-4 times higher in KO
compared to the other sources of n-3 PUFAs. However,
apparent digestibility was greater (P = 0.009) in SO com-
pared to KO-fed rats. This may be due to ~50% of DHA
being in PL form in KO, whereas DHA was entirely in
TG form in SO. DHA was also in TG form in the other
fish oils (MO and TO), yet apparent DHA digestibility
was not significantly different than KO-fed rats. In
human studies, absorption efficiency of DHA from KO
was similar to MO [27,28]. In our study, higher DHA
digestibility in SO, but not rats fed MO or TO may be
due to differences in the positional distribution of DHA
on the TG molecule. Christensen et al. [29] reported
DHA on the sn-2 position resulted in higher absorption
compared to the sn-1 and sn-3 position of the TG mole-
cule. While, the fatty acid position on the lipid structure
may be a factor affecting digestibility. Overall total lipid
digestibility was lowest (P < 0.02) in KO-fed rats which
may be accounted for by fatty acids in KO being asso-
ciated with PL. Amate and Ramirez [30] observed
reduced absorption of n-3 LC-PUFAs in rats fed PL-rich
pig brain. In contrast, infants and pre-term infants fed
LC-PUFA PL as egg lecithin improved fat absorption
[31,32]. In the brain, DHA are mainly associated with
phosphatidylethanolamine and phosphatidylserine [33],
whereas the predominant PL in egg is phosphatidylcho-
line [34]. Further studies are needed to clarify whether
different PLs influence fatty acid digestibility. This is
important because the source of PUFAs that provides
high digestibility also increases tissue deposition.
Brain PUFA Deposition
Epidemiological studies have linked low DHA to poor
neural development in infants and to cognitive decline
in the aging individuals [35]. In animals, decreased DHA
in the developing brain resulted in deficits in neurogen-
esis, neurotransmitters, visual function, and learning
[35]. In humans, PL contributes to ~25% of the dry
weight of the brain [36]. However, in our study DHA
was better incorporated when consumed in TG than PL
form. TO with the highest DHA in TG form resulted in
the highest (P < 0.001) brain DHA deposition. KO with
the highest DHA in PL form did not result in the high-
est brain deposition due to reduced DHA digestibility.
The higher DHA digestibility associated with SO also
resulted in the highest (P < 0.001) brain DHA deposi-
tion. Talahalli et al. [37] observed rats fed EPA+ DHA
increased brain DHA, but produced only a small
increase in EPA due to inefficient tissue uptake. Of the
marine oils, TO with the lowest EPA content resulted in
lower (P = 0.01) brain EPA deposition compared to rats
fed MO or FO. Dietary FO contained no detectable
EPA; therefore, EPA deposition in the brain tissue of
FO-fed rats suggested that de novo synthesis of the n-3
LC-PUFAs occurred in the brain.
Brain metabolism, function, and structure also depend
on adequate concentrations of ARA [38]. In our study,
the CO and FO diets had no detectable ARA, but the
highest LA content. In turn, brain LA content was high-
est (P < 0.001) in CO and FO-fed rats. Efficient metabo-
lism of LA to n-6 LC-PUFAs in the brain was indicated
by ARA deposition in rats fed CO and FO. Brain ARA
content in CO-fed rats was comparable to rats fed SO
and TO with the highest dietary ARA-TG content. On
the other hand, conversion of ALA to n-3 LC-PUFAs
was less efficient. Feeding rats FO, but not CO,
increased brain EPA. This may be due to higher ALA
content in the FO (14.6 ± 2.1 mg/g) than the CO (0.1 ±
0.01 mg/g) diet. Brain DHA deposition in rats fed CO
and FO diets containing no DHA indicated conversion
Table 8 The effect of feeding growing female rats different sources of omega-3 fatty acids on oxidative stability and
eicosanoid metabolism
Treatments
Measurements1 CO FO KO MO SO TO
Eicosanoids
PGE2 metabolite (μg/d) 2.2 ± 1.5 1.7 ± 1.1 4.6 ± 2.1 0.9 ± 0.04 1.3 ± 1.0 1.1 ± 0.3
TXB2 metabolite (μg/d) 1474 ± 665 991 ± 393 1653 ± 447 807 ± 248 1972 ± 808 1359 ± 431
Oxidative Stability
RBC TBARS (μM MDA/mL) 9.5 ± 0.6 9.2 ± 0.60 8.5 ± 0.2 9.4 ± 0.5 10.0 ± 0.6 9.6 ± 0.2
Serum TBARS (μM MDA/mL) 6.9 ± 0.4a 5.9 ± 0.2ab 6.5 ± 0.3a 6.8 ± 0.3a 5.1 ± 0.3b 5.2 ± 0.2b
Serum TAC(mM Trolox) 1.5 ± 0.2 1.1 ± 0.1 1.3 ± 0.1 1.5 ± 0.2 1.1 ± 0.2 1.2 ± 0.2
Liver TBARS (μM MDA/g Tissue) 220.3 ± 23.8b 235.6 ± 21.7b 265.1 ± 46.4b 435.0 ± 68.8a 198.3 ± 23.3b 177.5 ± 14.7b
Liver TAC (mM Trolox) 3832 ± 421ab 4203 ± 207ab 3542 ± 726b 5695 ± 727a 2726 ± 250b 2493 ± 195b
1Values are expressed as the mean ± SEM of n = 7 rats/group. Different superscript letters a, b within the same rows indicate significant differences at P < 0.05 by one-
way ANOVA followed by Tukey’s test. Abbreviations are CO, corn oil; FO, flaxseed oil; KO, krill oil; MO, menhaden oil; SO, salmon oil; TO, tuna oil; PGE2 , prostaglandin E2;
TXB2, thromboxane B2; RBC, red blood cells; TBARS, thiobarbituric acid reactive substances; MDA, malondialdehyde; TAC, total antioxidant capacity.
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Figure 1 The effect of feeding growing female rats different sources of omega-3 polyunsaturated fatty acids on gene expression of A)
glutathione-peroxidase (GSH-Px), B) copper/zinc superoxide dismutase (Cu/Zn SOD1), C) manganese superoxide dismutase (Mn SOD2),
and D) catalase. Values are relative mRNA expression after normalization to the GADPH housekeeping gene expressed as the means ± SEM (n
= 4-6). Abbreviations for diet treatments are CO, corn oil; FO, flaxseed oil; KO, krill oil; MO, menhaden oil; SO, salmon oil; TO, tuna oil.
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of ALA to n-3 LC-PUFAs. Several studies reported
increased brain DHA in rats fed ALA [39-42]. In our
study, rats fed SO and TO with pre-formed DHA had
significantly higher brain DHA deposition than FO or
CO-fed rats having no dietary DHA. The results indi-
cated greater brain incorporation of pre-formed DHA
compared to conversion of ALA to n-3 LC-PUFAs. KO
and MO also provided pre-form n-3 LC-PUFAs; how-
ever, DHA content provided by MO was low and KO
had reduced DHA digestibility. Due to limited biosynth-
esis of DHA in the mammalian brain, DHA deposition
in the brain relies on the diet and on the release of
DHA synthesized from ALA in the liver [33,43]. There-
fore, the effect of feeding different sources of n-3 PUFA
on liver fatty acid composition was evaluated.
Liver PUFA Deposition
The amount of dietary fatty acids affected liver deposi-
tion. Rats fed FO with the highest ALA content also had
the highest (P < 0.001) liver ALA deposition. Rats fed
SO with the highest dietary EPA-TG resulted in the
highest (P < 0.001) liver EPA deposition. Of the oil
sources, KO had the highest DHA content; however,
liver DHA deposition was highest (P < 0.001) in rats fed
TO and SO. TO provided the highest DHA in TG form
and SO-fed rats showed greater DHA digestibility than
KO. Liver DHA incorporation as TO was ~1.5 times
greater in the form of TG than PL in TO and SO-fed
rats, whereas DHA was equally incorporated as TG and
PL in KO-fed rats. Song and Miyazawa [12] reported
that rats fed DHA in PL form had lower liver DHA
incorporation compared to DHA fed in TG form.
The liver is a major site of LC-PUFA biosynthesis.
Therefore, n-3 LC-PUFA deposition is not only depen-
dent on the intake of pre-formed EPA and DHA, but it
also depends on intake of the precursor, ALA. Feeding
rats CO containing ALA and no n-3 LC-PUFAs resulted
in DHA, but no detectable EPA liver deposition. DHA
has a structural role, whereas EPA is preferentially uti-
lized for b-oxidation or eicosanoid synthesis [44]. Simi-
larly, FO contains no pre-formed n-3 LC-PUFA. Feeding
rats FO with the highest ALA content resulted in
detectable DHA as well as EPA deposition in the liver.
Still, conversion of ALA to n-3 LC-PUFAs resulted in
lower liver EPA and DHA deposition compared to con-
sumption of SO and TO with pre-formed n-3 LC-
PUFAs. Talahalli et al. [37] reported rats needed to con-
sume 12.5 times more ALA to produce the same liver
n-3 LC-PUFAs incorporation as rats consuming EPA
and DHA. This may be due to preferential use of ALA
in b-oxidation [45]. Also, several enzymes required for
synthesis of LC-PUFAs in the desaturation-elongation
pathway are inefficient [46].
On the other hand, there was efficient liver conversion
of LA to n-6 LC-PUFAs. This was indicated by similar
liver ARA deposition in rats fed CO containing no
detectable ARA compared to SO containing pre-formed
ARA. Additionally, liver ARA deposition was signifi-
cantly higher in CO than FO, KO or MO-fed rats. This
may have occurred because FO had the highest ALA
content followed by MO and KO. ALA and LA compete
for the same enzymes to form their respective LC-
PUFAs with ALA having higher affinity for the rate-lim-
iting Δ-6 desaturase [33]. This has important implica-
tions because decreased ARA reduces synthesis of pro-
thrombotic and inflammatory 2-series eicosanoids by
COX II. However, our study showed no significant dif-
ferences in the 2-series eicosanoids, PGE2 and TXB2
metabolites among the diet groups. Feeding rats FO,
which is high in ALA, decreased liver ARA, but this was
not accompanied by increased EPA deposition. Conver-
sely, feeding rats SO increased liver EPA, but this was
not accompanied by decreased ARA deposition. Further-
more, measurement of urinary PGE2 and TXB2 metabo-
lites provided an indicator of systemic rather than tissue
change. Responses to n-3 PUFA intakes are not uniform
among tissues. For example, liver fatty acid composition
may vary depending on the uptake of chylomicron rem-
nants from the circulation [47]. Also, the liver not being
a major storage organ is less responsive to the diet than
adipose tissues [37]. Recent research suggests changing
the fatty acid profile of adipose tissue results in health
benefits by altering lipid metabolism and adipokine
secretion [48,49]. Therefore, the effect of consuming dif-
ferent n-3 PUFA sources on adipose tissue PUFA com-
position was determined.
Adipose Tissues PUFA Deposition
As the chief site for lipid storage, the fatty acid profile of
adipose tissue reflected the diet. Rats fed KO with the
highest amount of EPA had the highest (P < 0.001) adi-
pose tissue EPA deposition. Rats fed FO with the high-
est amount of ALA content had the highest (P < 0.001)
adipose tissue ALA deposition. Talahalli et al [37]
reported rats fed increasing doses of ALA resulted in a
linear increase in ALA accumulation in the adipose tis-
sue. In our study, rats fed FO increased n-3 PUFA
deposition in the adipose due to the high dietary ALA
content. Additionally, rats fed KO and MO increased
adipose n-3 PUFA deposition. Others also reported
feeding rats fish oils increased n-3 LC-PUFA incorpora-
tion in the adipose tissue [50-53]. Increasing adipose tis-
sue n-3 PUFA incorporation has been observed to
reduce adipose mass [48]. However, in our study, there
was no significant reduction in the adipose mass of rats
fed different n-3 PUFA sources.
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The adipose tissue is another site of LC-PUFA bio-
synthesis. Efficient conversion of LA to n-6 LC-PUFAs
in gonadal adipose was indicated by rats fed FO and CO
containing no ARA having similar tissue ARA deposi-
tion to rats fed MO, KO or SO containing pre-formed
ARA. In retroperitoneal adipose, rats fed CO had similar
tissue ARA to rat fed marine oils. FO also resulted in
tissue ARA, but lower (P < 0.001) amounts than rats fed
CO or marine oils. This may be due to FO having the
highest ALA content. High ALA competitively inhibits
LA, the precursor of ARA.
Conversion of ALA to n-3 LC-PUFAs was less effi-
cient. In our study, there were no detectable EPA and
DHA in the adipose of CO-fed rats. However, rats fed
FO containing ALA, but no DHA, resulted in DHA
deposition in gonadal and not in retroperitoneal adipose
tissue. This suggested conversion of ALA to n-3 LC-
PUFAs was less efficient in retroperitoneal adipose com-
pared to gonadal adipose. Muhlhausler et al. [49]
observed female rats fed n-3 PUFA had different degrees
of responsiveness to PUFA deposition and in turn, tissue
PUFAs induced changes in lipogenic gene expression.
Furthermore, gene expression changes were more pro-
nounced in the omental compared to retroperitoneal
adipose tissue.
Rats fed FO and marine oils had an adipose tissue n-
6/n-3 ratio of 1:1-1:2. An n-6/n-3 ratio of ~1:1 in tissues
has been reported to reduce atherosclerosis due to the
inhibition of systemic and vascular inflammation in apo-
lipoprotein E-deficient mice [54]. While the optimal n-
6/n-3 ratio in tissues has not been defined, increasing
tissue unsaturation has been considered to be health
beneficial. However, the higher tissue unsaturation
needs to be considered since a greater number of double
bonds increases tissue susceptibility to lipid
peroxidation.
Oxidative Stability
DHA is particularly susceptible to lipid peroxidation due
to its high degree of unsaturation [11]. Our study
showed rats fed TO, the highest source of DHA of the
fish oils or SO with the high DHA digestibility resulted
in lower (P = 0.005) serum TBARS compared to all diet
groups, except FO-fed rats. However, there were no sig-
nificant differences in RBC TBARS among the diet
groups. Oxidative stress occurs when accumulation of
oxidative products overwhelms the body’s antioxidant
capacity. TAC measures endogenous antioxidant, dietary
antioxidant, and interactions between antioxidants [55].
In our study, serum TAC was not significantly different
among the diet groups. Circulating TBARS and TAC
may not reflect the tissue concentration.
The liver is a primary target for oxidative stress-
induced damage in oil-fed rats [12]. Rats fed MO had
the highest (P = 0.03) liver TBARS. The TBARS assay is
accepted as an index of oxidative stress; however, this
method quantifies MDA-like compounds and does not
specifically measure lipid peroxidation [56]. Further-
more, it is the imbalance of oxidants and antioxidants
that leads to oxidative stress. Reena and Lokesh [57]
reported that the lipid peroxides generated by feeding
rats PUFAs was partly nullified by the capability of
PUFAs to increased liver antioxidant enzymes, Cu/Zn
SOD, Mn SOD, CAT, and GSH-Px. Extracellular and
cytosolic forms of SOD depend on Cu/Zn and in the
mitochondria SOD depends on Mn. SOD detoxifies
superoxide radicals giving rise to hydrogen peroxide
(H2O2). H2O2 is a potent free radical generator and can
generate hydroxyl radicals, which induce lipid peroxida-
tion of cell membranes. Therefore, to prevent accumula-
tion of H2O2, it is important that enhanced SOD
activity be accompanied by increased cellular CAT and
GSH-Px [58]. Ruiz-Gutierrez et al. [59] reported
increased n-3 PUFAs enhanced the efficiency of the
antioxidant defense system.
In our study, rats fed SO and TO had a P:S ratio of
3:1 compared the range of 2:1 to 1.2:1 in the other treat-
ment groups. However, liver TAC was higher in MO (P
= 0.03) than TO or SO-fed rats. According to Venkatra-
man et al. [60], different lipids had differential effects on
the antioxidant defense system at the molecular level.
Mice fed MO and KO had higher liver SOD, CAT, and
GSH-Px mRNA expression than rats fed CO [60]. In
our study, there were no significant differences in SOD
or CAT gene expression in rats fed different sources of
n-3 PUFAs. Rats fed fish oils increased GSH-Px mRNA
expression compared to CO or FO-fed rats, although
this was not statistically significant. Demoz et al. [15]
reported that mice provided high doses of EPA
enhanced liver antioxidant enzyme activities. In our
study, EPA was in TG form in SO, whereas in KO
~27% of EPA was in PL form. In turn, liver deposition
of EPA as PL was ~50% in KO-fed rats compared to
~40% EPA the SO-fed rats. Additionally, KO also con-
tains high amounts of the powerful antioxidant, astax-
anthin [61,62]. However, in the present study there were
no significant differences in SOD, CAT or GSH-Px
mRNA expression in rats fed KO compared to the other
diet groups.
Conclusions
The present study evaluated popular sources of n-3
PUFA as well as KO, a novel source of n-3 PUFAs.
Higher PL content in KO compared to fish oils has lead
to commercial claims of enhanced digestibility which
improves n-3 PUFA tissue deposition and greater oxida-
tive stability. Based on our results, rats fed KO had
lower DHA digestibility and brain incorporation
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compared to the fish oil sources, SO and TO. Despite
KO being rich in the antioxidant astaxanthin [26,62],
lipid oxidation was not decreased and gene expression
of antioxidant defense enzymes was not increased. On
the other hand, rats fed SO and TO had the highest n-3
PUFAs digestibility and in turn, tissue accretion. Lipid
oxidation was not increased in either SO or TO-fed rats
despite higher tissue DHA deposition. On the basis that
the optimal n-3 PUFA sources should provide high
digestibility and efficient tissue incorporation with the
least tissue lipid peroxidation, TO and SO appeared to
be the sources of n-3 PUFAs most favorable to health.
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